Roche: FDA Approves Genentech’s Wilserdly For ER-Positive, ESR1-Mutated Advanced Breast Cancer
Oral SERD Giredestrant Expected To Be Available In US In Coming Weeks - Eligible Commercially Insured Patients May Pay As Little As $0 Through Genentech s Co-Pay Assistance Programme